1185767-06-9

Basic information

• Product Name: 5-bromo-6-fluoro-1-methyl-1H-indazole
• Synonyms: 5-bromo-6-fluoro-1-methyl-1H-indazole
• CAS NO: 1185767-06-9
• Molecular Formula: C8H6BrFN2
• Molecular Weight: 229.0490432
• Mol File: 1185767-06-9.mol

Chemical Properties

• Boiling Point: 293.4±20.0 °C(Predicted)
• Appearance: /
• Density: 1.70±0.1 g/cm3(Predicted)
• PKA: -0.04±0.30(Predicted)
• CAS DataBase Reference: 5-bromo-6-fluoro-1-methyl-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-6-fluoro-1-methyl-1H-indazole(1185767-06-9)
• EPA Substance Registry System: 5-bromo-6-fluoro-1-methyl-1H-indazole(1185767-06-9)

Safety Data

• Hazardous Substances Data: 1185767-06-9(Hazardous Substances Data)

Upstream product

• 105391-70-6 5-bromo-6-fluoro-1H-indazole 
• 74-88-4 methyl iodide 

Downstream Products

• 1185767-05-8 6-fluoro-1-methyl-1H-indazole-5-carbaldehyde 

Relevant articles and documents

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

HETEROCYCLIC OXIME COMPOUNDS

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS

The invention relates to compounds of formula (I) and salts thereof, wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with

IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE

The invention relates to compounds of formula (I) and salts thereof, formula (I) wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharamaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).